1957RoC is founded in Paris
Cosmétique Médicale S.A. is founded by Dr. Jean-Charles Lissarrague, a Doctor of Pharmacy. RoC becomes France’s first hypo-allergenic skincare brand. That year, RoC also launches “Écran total RoC,” the first sunscreen combining chemical and physical protectants for both UVA and UVB coverage.
1958Dr. Jean-Charles Lissarrague publishes a medical paper on lipstick allergies
Published in the Bulletin de la Société de Dermo-Pharmacie.
1960RoC begins partnering with dermatologists on research
Today, L.I.F.E. (Learning, Ideation, Formulation, Evaluation) brings dermatologists into product development.
1983RoC S.A. obtains Pharmaceutical Laboratory status
The company, founded as Cosmétique Médicale S.A., became RoC-Cosmétique Médicale S.A. in 1965 and RoC S.A. in 1968.
1984RoC patents a method for verifying formulas as non-comedogenic
The work makes RoC one of the first non-comedogenic brands.
1987RoC launches Myosphère
Myosphère is the first liposomal skincare emulsion sold in pharmacies.
1989RoC ends animal testing
RoC ends animal testing in August 1989. Today, RoC is listed by PETA.
1993RoC forms a U.S. joint venture with Dermik Laboratories
A joint venture with Dermik Laboratories, Inc. markets and distributes RoC products in the U.S.
1995Retinol Actif Pur launches
RoC becomes the first to stabilize retinol in a skincare product.
1999Retinol Line Smoothing Eye Cream launches
The launch expands RoC’s retinol portfolio.
2001
The “10 Years Back” claim is clinically validated
2003
The “10 Years Back” claim launches with Retin-OX
2015RoC publishes a one-year retinol clinical study
The study shows that benefits do not plateau after one year of use.
2020RoC launches its first retinol capsules
Retinol Correxion Capsules bring RoC’s retinol into capsule format for the first time.
2022Derm Correxion launches
The line is developed with dermatologists and inspired by in-office procedures.
Its hero product, Fill + Treat, is a filler-inspired anti-wrinkle serum featuring a patent-pending retinol complex.
2023RoC launches Revive + Glow Vitamin C Eye Balm
The product is RoC’s first eye balm.
2024RoC launches the Derm Correxion Firming Serum Stick
RoC’s first Retinol Firming Stick becomes the #1 new serum launch in the U.S. in 2024¶.
2024RoC returns to France
RoC Skincare France opens in Paris and RoC relaunches in French pharmacies.
2024RoC Retinol Genome Study is first presented in Paris
The ex vivo study is first presented at the RoC France launch PR event in September 2024.
It is later presented at the American Academy of Dermatology (AAD) Annual Meeting in March 2026.
2024RoC 35 launches with Look as Young as You Feel
RoC introduces its new brand platform, Look as Young as You Feel, with RoC 35, its five-product protocol tested across 35 French clinics.
2025Derm Correxion Lip Volumizer launches
RoC introduces its first Lip Volumizing Treatment, extending the Derm Correxion line into a topical lip treatment inspired by in-office procedures. It becomes the #1 new U.S. skincare launch in Q4 2025‖. It has received six beauty awards since its launch.
2025RoC completes a retinol stability study
RoC completes a study benchmarking the stability of 35 retinoid formulas.
Results are later presented at AAD in March 2026.
2025RoC forms its Longevity Council and establishes a research fund with a leading U.S. university to study the biology of aging
The initiatives extend RoC’s work beyond traditional anti-aging claims into research on aging and skin over time.
2026U.S. Patent 12,521,335 is granted
The U.S. patent covers RoC’s stabilized Vitamin C + Peptides combination, used in Revive + Glow Daily Serum and the reformulated Revive + Glow Vitamin C Eye Balm.
2026Dr. Angela Lamb becomes RoC’s Chief Dermatologist
She chairs both the Derm Advisory Board and the Longevity Council.
2026RoC presents new retinol science at AAD
The company presents its ex vivo Retinol Genome Study and an ex vivo Patented Clinical Retinol vs. Retinal explant study.
RoC also presents first results from a pilot clinical study of Clinical Retinol in identical twins.
2026RoC expands its Clinical Retinol research in identical twins
RoC begins recruiting at least 30 pairs of female identical twins in the U.S. for an expanded 12-week clinical study.
The study combines RoC’s standard clinical skin measures with biometric data from Oura Ring to examine how Clinical Retinol and lifestyle relate to visible skin aging and skin longevity.
Clinical assessments include expert grading, digital photography, corneometer readings and subject self-assessment. Oura Ring data include measures such as sleep, stress, heart rate, heart rate variability and temperature trends.
Results are expected in mid-2027.
2026RoC launches Retinol Correxion Line Smoothing Triple Serum
A clinical study shows a visible 7-year reduction in skin age in 4 weeks†.
Triple Serum is a patent-pending formula combining hyaluronic acid, micro-encapsulated retinol and PDRN. This (vegan) PDRN is ginseng-derived and inspired by ingredients used in aesthetic procedures. It is formulated to visibly smooth skin.
2026RoC launches Retinol Correxion Line Smoothing 2-Step Peel Pads
The Peel Pads bring Patented Clinical Retinol into an at-home format inspired by professional peels.
2026RoC’s Mind the Gap study quantifies the felt-age gap
The study surveys 6,818 women ages 35 and over across 12 countries.
Women report feeling nine years younger than their chronological age on average, with an average felt age of 46 compared with an average chronological age of 55.